4 research outputs found
AGT haplotype in ITGA4 gene is related to antibody-mediated rejection in heart transplant patients
[Abstract] Introduction.
One of the main problems involved in heart transplantation (HT) is antibody-mediated rejection
(AMR). Many aspects of AMR are still unresolved, including its etiology, diagnosis and
treatment. In this project, we hypothesize that variants in genes involved in B-cell biology in
HT patients can yield diagnostic and prognostic information about AMR.
Methods.
Genetic variants in 61 genes related to B-cell biology were analyzed by next generation
sequencing in 46 HT patients, 23 with and 23 without AMR.
Results.
We identified 3 single nucleotide polymorphisms in ITGA4 gene (c.1845G>A, c.2633A>G,
and c.2883C>T) that conformed the haplotype AGT-ITGA4. This haplotype is associated
with the development of AMR. Moreover, AMR patients with the haplotype AGT-ITGA4
present lower levels of integrin α-4 in serum samples compared to the reference GAC haplotype
in control patients.
Conclusion.
We can conclude that polymorphisms in genes related to the biology of B-cells could have
an important role in the development of AMR. In fact, the AGT haplotype in ITGA4 gene
could potentially increase the risk of AMR.Instituto de Salud Carlos III; PI13/0217
ISCHEMIA trial: How to apply the results to clinical practice
During the last years two questions have been continuously asked in chronic coronary syndromes: (1) Do revascularization procedures (coronary artery bypass grafting or percutaneous coronary intervention) really improve symptoms of angina? and (2) Do these techniques improve outcomes, i.e. do they prevent new myocardial infarction events and cardiovascular death? Therefore, there was a need for a large definitive trial. This study was the ISCHEMIA trial, a large, multicentric trial sponsored by the National Heart, Lung, and Blood Institute. The main trial compared coronary revascularization and optimal medical treatment (OMT) vs OMT alone in 5179 patients enrolled after a stress test. During a median 3.2-year follow-up, 318 primary outcome events occurred; the adjusted hazard ratio for the invasive strategy as compared with the conservative strategy was 0.93 (95% confidence interval 0.80-1.08, P = 0.34). The ISCHEMIA trial deeply disrupted many of our prior attitudes regarding management strategies for patients with stable coronary artery disease. The findings underscore the benefits of disease-modifying OMT for stable coronary artery disease patients. The main purposes of ischemia assessment before this trial were: Diagnostic purposes, assessment of outcome, and adding to decision-making processes. Obviously, this changed after the trial results. The results of ISCHEMIA might challenge the current diagnostic approach for stable angina patients recommended in the last European Society of Cardiology guidelines on chronic coronary disease that were based on studies published before the ISCHEMIA trial. In this editorial we propose our approach based on the ISCHEMIA study and the pretest probability for a positive test in patients with chronic coronary syndromes
Gu?a r?pidas de consultor?a telef?nica m?dica y de enfermer?a
Gu?a de consulta para o persoal m?dico e de enfermar?a que desenvolve o seu traballo en centros de coordinaci?n telef?nica para a atenci?n ?s urxencias e ?s emerxencias sanitarias. Est? estruturada en 12 cap?tulos nos que describen os principais protocolos de actuaci?n para a asistencia ?s patolox?as m?is com?ns atendidas no ?mbito de urxencias extra hospitalarias.Gu?a de consulta para el personal m?dico y de enfermer?a que desarrolla su trabajo en centros de coordinaci?n telef?nica para la atenci?n a las urgencias y a las emergencias sanitarias. Est? estructurada en 12 cap?tulos en los que describen los principales protocolos de actuaci?n para la asistencia a las patolog?as m?s comunes atendidas en el ?mbito de urgencias extra hospitalarias